Antitumor Drugs, Breast Cancer, Cardiac Toxicity
Conditions
Keywords
Cardiac Toxicity, Antitumor drugs, Breast Cancer, Trastuzumab
Brief summary
According to the existing clinical data in our hospital, retrospective study was conducted to screen the risk factors with predictive value for TRC(trastuzumab-related cardiotoxicity) risk, and to construct the risk prediction model for TRC.
Detailed description
The breast cancer patients with cardiotoxicity caused by trastuzumab were selected as the case group, and the breast cancer patients without cardiotoxicity were selected as the control group. The clinical baseline data, echocardiographic parameters and serum markers of the case group and the control group were compared to find out the risk factors that may have predictive value for the risk of TRC. The target factors were analyzed by univariate analysis and multivariate Logistic regression analysis, and the TRC risk prediction model was established.
Interventions
DRUGTrastuzumab
Trastuzumab \[Herceptin\] is a recombinant DNA-humanized monoclonal antibody that selectively targets the HER-2 receptor on the surface of tumor cells.
Sponsors
Peking University Third Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Female patients diagnosed with HER2-positive breast cancer treated in our hospital. 2. Surgical treatment combined with chemotherapy or radiotherapy was completed according to NCCN guidelines, and trastuzumab standard treatment was received for at least half a year. (3) Cardiac function (including echocardiography or biomarkers) was assessed at least once within 3 months before trastuzumab treatment, and at least once during or after treatment was performed for heart-related tests. (4) Complete case data.
Exclusion criteria
1. Patients who have not been properly treated with trastuzumab or have been treated for less than half a year; 2. Patients who did not receive cardiac function assessment before trastuzumab treatment, during or after treatment; 3. Patients whose case data were missing or lost to follow-up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cardiac toxicity | 12 months | The asymptomatic LVEF decreases ≥ 10% of the baseline value or to an absolute value \< 50% |
Countries
China
Outcome results
None listed